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Abstract: Indigenous Australian children have the world's highest recorded rate of bronchiectasis. 
Despite a lack of high-level evidence on effectiveness and antibiotic resistance, long-term antibiotics 
are often prescribed as part of their clinical management.  We determined the impact of recent 
macrolide (primarily azithromycin) and beta-lactam antibiotic use on nasopharyngeal colonisation, 
lower airway infection (>10^4 colony-forming units/mL in bronchoalveolar lavage fluid culture) and 
antibiotic resistance in nontypeable Haemophilus influenzae (NTHi), Streptococcus pneumoniae and 
Moraxella catarrhalis isolates from 104 Indigenous children with radiographically-confirmed 
bronchiectasis.  Recent antibiotic use was associated with reduced nasopharyngeal carriage of these 
respiratory bacterial pathogens, especially S.  pneumoniae (Odds Ratio [OR] 0.22, 95% Confidence 
Interval [CI] 0.08, 0.63) and M. catarrhalis (OR 0.33, 95% CI 0.11, 1.01) in 39 children who received 
macrolides, and S. pneumoniae (OR 0.07, 95% CI 0.01, 0.32) in 26 children who received beta-lactam 
antibiotics. In the lower airways, only M. catarrhalis infection was reduced in children who received 
macrolides, but this was not statistically significant (OR 0.18, 95% CI 0.00, 1.75). Children given 
macrolides were more likely to carry (OR 4.58, 95% CI 1.14, 21.7) and be infected by (OR 8.13, 95% CI 
1.47, 81.3) azithromycin-resistant S. pneumoniae. Children receiving beta-lactam antibiotics were 
more likely to have lower airway infection with ampicillin-resistant NTHi (OR 4.40, 95% CI 0.85, 23.9). 
Increased risk of lower airway infection by antibiotic-resistant pathogens in children receiving 
antibiotics is of concern and clinical trials to determine if long-term antibiotic treatments provide an 
overall clinical benefit in this setting are awaited. 
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Abstract 1 
Indigenous Australian children have the world’s highest recorded rate of bronchiectasis. 2 
Despite a lack of high-level evidence on effectiveness and antibiotic resistance, long-term 3 
antibiotics are often prescribed as part of their clinical management.  We determined the 4 
impact of recent macrolide (primarily azithromycin) and beta-lactam antibiotic use on 5 
nasopharyngeal colonisation, lower airway infection (>10
4
 colony-forming units/mL in 6 
bronchoalveolar lavage fluid culture) and antibiotic resistance in nontypeable Haemophilus 7 
influenzae (NTHi), Streptococcus pneumoniae and Moraxella catarrhalis isolates from 104 8 
Indigenous children with radiographically-confirmed bronchiectasis.  Recent antibiotic use 9 
was associated with reduced nasopharyngeal carriage of these respiratory bacterial pathogens, 10 
especially S.  pneumoniae (Odds Ratio [OR] 0.22, 95% Confidence Interval [CI] 0.08, 0.63) 11 
and M. catarrhalis (OR 0.33, 95% CI 0.11, 1.01) in 39 children who received macrolides, and 12 
S. pneumoniae (OR 0.07, 95% CI 0.01, 0.32) in 26 children who received beta-lactam 13 
antibiotics. In the lower airways, only M. catarrhalis infection was reduced in children who 14 
received macrolides, but this was not statistically significant (OR 0.18, 95% CI 0.00, 1.75). 15 
Children given macrolides were more likely to carry (OR 4.58, 95% CI 1.14, 21.7) and be 16 
infected by (OR 8.13, 95% CI 1.47, 81.3) azithromycin-resistant S. pneumoniae. Children 17 
receiving beta-lactam antibiotics were more likely to have lower airway infection with 18 
ampicillin-resistant NTHi (OR 4.40, 95% CI 0.85, 23.9). Increased risk of lower airway 19 
infection by antibiotic-resistant pathogens in children receiving antibiotics is of concern and 20 
clinical trials to determine if long-term antibiotic treatments provide an overall clinical 21 
benefit in this setting are awaited. 22 
Key words: azithromycin, bronchiectasis, microbial drug resistance, nasopharynx,  23 
                     respiratory tract infections. 24 
                     25 
 4 
1.  Introduction  1 
The role of bacteria in children with non-cystic fibrosis (CF) bronchiectasis has received 2 
surprisingly little attention [1]. Indigenous Australian children have a heavy burden of 3 
respiratory disease [2]. Within weeks of birth their upper airways are colonised by 4 
Streptococcus pneumoniae (pneumococcus), nontypeable Haemophilus influenzae (NTHi) 5 
and Moraxella catarrhalis [3].  We recently presented evidence indicating that recurrent 6 
pulmonary aspiration of bacterial-laden nasopharyngeal secretions might be important in the 7 
pathogenesis of non-CF bronchiectasis in this high-risk group of children [4]. 8 
 9 
The prescription of long-term maintenance antibiotics, such as azithromycin, is sometimes 10 
used to treat adults and children with non-CF bronchiectasis. However, the overall effects of 11 
azithromycin in these patients are uncertain.  Although a small randomised controlled trial 12 
and retrospective reviews from several centres managing adults with non-CF bronchiectasis 13 
report that azithromycin improves exacerbation frequency and spirometry, and suppresses 14 
sputum bacteria [5-7], higher-level evidence for efficacy is lacking.  Moreover, azithromycin 15 
can lead to macrolide resistance in respiratory flora [8], an increasing problem worldwide [9]. 16 
Consequently, substantial gaps in our knowledge remain over the effects of azithromycin on 17 
the upper and lower airway microbiology of children with non-CF bronchiectasis.   18 
Moreover, uncertainty surrounds clinically relevant antimicrobial resistance breakpoints for 19 
bacterial pathogens acting at separate anatomical sites within the respiratory tract [10]. 20 
 21 
In this prospective, cross-sectional, observational study we examined the impact of recent 22 
antibiotic exposure upon nasopharyngeal colonisation, lower airway infection and antibiotic 23 
resistance in common respiratory bacterial pathogens detected in Indigenous children 24 
 5 
undergoing bronchoscopy following a radiographically-confirmed diagnosis of 1 
bronchiectasis. 2 
 3 
2. Methods 4 
2.1 Study participants 5 
Children referred for evaluation of persistent wet cough and/or recurrent lower respiratory 6 
infections were enrolled into the study between July 2007 and September 2011 inclusive. All 7 
participants had flexible bronchoscopy and high-resolution computed tomography under 8 
general anaesthesia for diagnostic evaluation of suspected bronchiectasis at the Royal Darwin 9 
Hospital, Northern Territory (NT), Australia.  Non-Indigenous children or those not found to 10 
have radiographically-confirmed bronchiectasis were excluded from this analysis, as were 11 
those found to have cystic fibrosis. The Human Research Ethics Committee of the NT 12 
Department of Health and Menzies School of Health Research approved the study. The 13 
children’s carers provided written, informed consent.    14 
 15 
 2.2 Data collection 16 
Clinical information was extracted from the medical records using a standardised data 17 
collection form.  A diagnosis of radiographically-confirmed bronchiectasis was made by the 18 
treating paediatric respiratory physician based on the standard criteria for the assessment of 19 
high resolution CT scans.  Recent antibiotic use was defined as having received any antibiotic 20 
within the 2 week period prior to bronchoscopy.   21 
 22 
2.3 Specimen collection and storage 23 
Immediately after anaesthetic induction, a rayon-tipped swab was inserted into the 24 
nasopharynx, rotated for 2-3 seconds before being withdrawn and placed into a tube 25 
 6 
containing 1mL of skim milk tryptone glucose glycerol broth (STGGB) [4]. This was 1 
followed by transnasal flexible bronchoscopy as previously outlined [4] so that suction 2 
channel use was avoided until the bronchoscope tip extended below the carina.  3 
Bronchoalveolar lavage (BAL; 1 mL/kg; maximum 20mL sterile saline) was conducted on 4 
the most abnormal appearing lobe identified on radiography or at bronchoscopy in 5 
accordance with the European Respiratory Society’s guidelines [11], followed by immediate 6 
suctioning into a mucus trap. A 0.5 mL aliquot of BAL fluid was added to a cryovial 7 
containing 0.5mL of concentrated STGGB for bacterial culture. The BAL fluid and 8 
nasopharyngeal swab specimens were transferred to the laboratory for storage at -80
o
C.  9 
 10 
2.4 Laboratory procedures 11 
Specimens were thawed, mixed and 10µL aliquots plated onto selective media. Semi-12 
quantitative colony counts were performed and correlated to density of colony-forming units 13 
(CFU)/mL in BAL fluid by serial dilution and quantitative colony counts, and bacterial 14 
species were identified according to standard procedures [4]. Lower airway infection was 15 
diagnosed when any single respiratory bacterial pathogen was grown in concentrations >10
4
 16 
CFU/mL in BAL fluid cultures [4]. 17 
 18 
From each positive specimen, up to four colonies each of S. pneumoniae and NTHi were 19 
tested for antibiotic susceptibility using the calibrated disc sensitivity (CDS) method [12].  20 
Minimum inhibitory concentrations (MICs) for penicillin and azithromycin (S. pneumoniae) 21 
and for ampicillin and azithromycin (NTHi) were determined by Etest® strips (AB Biodisk 22 
[now AB bioMérieux], Sweden) when the respective disc annuli were <6mm.  Resistance 23 
was defined according to the Etest® guidelines, except for H. influenzae resistance to 24 
azithromycin where the European Committee on Antimicrobial Susceptibility Testing 25 
 7 
(EUCAST) breakpoints were used; these include a category for intermediate resistance [13]. 1 
NTHi and M. catarrhalis isolates were tested for beta-lactamase (BL) activity employing a 2 
nitrocephin-based test. S. pneumoniae isolates were serotyped by the Quellung reaction with 3 
pneumococcal antisera (Statens Serum Institute, Copenhagen, Denmark).  4 
 5 
2.5 Statistical analyses 6 
Stata software (Stata Corporation, College Station, TX, Version 10.0) was employed for 7 
statistical analyses. Fisher’s exact test examined differences in categorical variables.  Odds 8 
Ratios (OR) were estimated from 2 x 2 tables with confidence intervals (CI) calculated by the 9 
exact binomial method. A two-tailed P-value <0.05 was considered significant. 10 
 11 
3. Results 12 
3.1 Details of participants 13 
Of 117 children admitted for evaluation of chronic wet cough, 107 had radiographically-14 
confirmed bronchiectasis. This study describes the 104 Indigenous children with confirmed 15 
bronchiectasis; 64 (62%) were male and the median age was 28.5 (range 5.2-154.6) months. 16 
Of these 104 children, 65 had taken antibiotics within 2 weeks of bronchoscopy, including 39 17 
who received macrolides (azithromycin 38, roxithromycin 1) and 26 who were prescribed 18 
beta-lactams singly or in combination (benzylpenicillin 3, amoxicillin 19, ampicillin 2, 19 
flucloxacillin 1, ceftriaxone 10, cefotaxime 2, cephalexin 1, meropenem 1). Four children 20 
received antibiotics from both classes, and nine received other antibiotics (trimethoprim-21 
sulphamethoxazole 3, metronidazole 1, gentamicin 1, vancomycin 3, unknown 3), five in 22 
combination with beta-lactams.   23 
 24 
 8 
Overall, 88/104 (85%) children had received at least two doses of the 7-valent pneumococcal 1 
conjugate vaccine (Prevenar®; Pfizer Australia Pty Ltd), and 58/84 (69%) of those aged ≥18 2 
months had been given the 23-valent pneumococcal polysaccharide vaccine (Pneumovax®; 3 
Commonwealth Serum Laboratories Ltd) as recommended by the NT immunisation schedule 4 
up to October 2009. The 10-valent pneumococcal H. influenzae protein D conjugate vaccine 5 
(Synflorix®; GlaxoSmithKline Australia Pty Ltd) replaced Prevenar® in the NT schedule in 6 
October 2009 and 13 (12.5%) children had received at least two doses of this vaccine. 7 
 8 
3.2 Pathogen recovery 9 
The three main respiratory bacterial pathogens detected in the nasopharynx (Table 1) were H. 10 
influenzae (n=52), S. pneumoniae (n=38) and M. catarrhalis (n=33). Lower airway infection 11 
(>10
4
 CFU/mL) was diagnosed in 42 (40%) children who grew H. influenzae (n=32), S. 12 
pneumoniae (n=17) and M. catarrhalis (n=12) in their BAL fluid cultures (Table 2). Two of 13 
52 children with H. influenzae nasopharyngeal carriage had typeable (non-Hib) strains only. 14 
All 32 children with H. influenzae lower airway infection had NTHi isolated, and typeable 15 
(non-Hib) strains were also found in three. Nasopharyngeal carriage of any of the three 16 
respiratory bacteria was significantly lower in children who received antibiotics within 2 17 
weeks of bronchoscopy (Table 3). For individual bacteria, reduced carriage was statistically 18 
significant for S. pneumoniae in children receiving macrolide or beta-lactam antibiotics. 19 
Reduced M. catarrhalis carriage in children receiving macrolides just failed to achieve 20 
statistical significance. No significant effects were seen for lower airway infection (Table 3). 21 
 22 
3.3 Antibiotic resistance  23 
Of 38 children with positive S. pneumoniae nasopharyngeal cultures, 13 (34%) carried 24 
azithromycin-resistant (MIC >4 mg/L) strains and 11 (29%) had penicillin non-susceptible 25 
 9 
(MIC >0.12 mg/L) strains (Table 4). In 17 children with S. pneumoniae lower airway 1 
infection, 10 (59%) had azithromycin-resistant strains and 6 (35%) had penicillin non-2 
susceptible strains isolated from BAL fluid (Table 5).  The azithromycin-resistant 3 
pneumococcal serotypes were 6A, 6C, 7C, 7F, 9N, 11A, 15C, 17F, 19F, 22F, 23B, 23F and 4 
31 and penicillin non-susceptible serotypes were 6B, 6C, 11A, 15C, 16F, 19A, 19F, 23B and 5 
35B.  Pneumococcal serotypes detected in children with lower airway infection are shown in 6 
Table 6. No isolates with high-level penicillin resistance (MIC ≥2 mg/L) or very high-level 7 
azithromycin resistance (MIC > 256 mg/L) were detected. Azithromycin MICs had a bimodal 8 
distribution and were either <1 mg/L (susceptible) or between 12 and 128 mg/L (resistant).  9 
 10 
Amongst 52 children with positive nasopharyngeal cultures for H. influenzae, two carried 11 
typeable (non-Hib) strains only, which were not tested for antibiotic resistance. MICs were 12 
also not determined for NTHi isolates from a further two nasopharyngeal cultures and two 13 
BAL fluid cultures. Using EUCAST breakpoints, azithromycin-resistant isolates (MIC >4 14 
mg/L) were detected in 3 of 48 (6%) nasopharyngeal swabs from culture-positive children 15 
(Table 4), and in 4 of 30 (13%) BAL specimens from children with NTHi lower airway 16 
infection (Table 5). Most NTHi-positive specimens (94% nasopharyngeal swabs and 87% 17 
from NTHi lower airway infection) had isolates with intermediate resistance to azithromycin 18 
(MIC >0.125 and ≤4 mg/L), while none tested were susceptible by EUCAST criteria (MIC 19 
≤0.125 mg/L).  20 
 21 
In the 48 NTHi nasopharyngeal culture positive children tested, 9 (19%) had BL-positive 22 
strains and 7 (15%) had ampicillin-resistant (MIC ≥4 mg/L) isolates.  In the 30 children 23 
tested with NTHi lower airway infection, 10 (33%) harboured BL-positive strains and 9 24 
(30%) had ampicillin-resistant strains. No BL-negative ampicillin-resistant (BLNAR) NTHi 25 
 10 
isolates were detected. Most (91%) of the 33 M. catarrhalis nasopharyngeal culture-positive 1 
children and all 12 children with M. catarrhalis lower airway infection had BL-positive 2 
strains. 3 
 4 
3.4 Impact of antibiotic use on antibiotic resistance  5 
Children who received macrolides were significantly more likely to harbour azithromycin-6 
resistant S. pneumoniae isolates in their nasopharynx and to have lower airway infections 7 
from these strains than children without a history of recent macrolide antibiotic therapy 8 
(Table 7). Similarly, those who received beta-lactam antibiotics were significantly more 9 
likely to have lower airway infection with ampicillin-resistant BL-positive NTHi than 10 
children who had not been exposed recently to these agents. Finally, those taking macrolides 11 
were less likely to have a lower airway infection caused by a BL-positive strain of  12 
M. catarrhalis.    13 
 14 
4.  Discussion 15 
To the best of our knowledge this is the first report describing the impact of antibiotics upon 16 
nasopharyngeal carriage of M. catarrhalis and on lower airway infection with any of the 17 
three major respiratory bacterial pathogens in children with non-CF bronchiectasis. 18 
Nasopharyngeal carriage by the three respiratory pathogens was lower in children who had 19 
received antibiotics in the 2-weeks prior to bronchoscopy. This effect upon carriage appeared 20 
to arise principally from the suppression of S. pneumoniae by macrolide and beta-lactam 21 
antibiotics and probably from a similar effect of macrolides upon M. catarrhalis. Studies in 22 
Australian Indigenous children treated for acute otitis media have shown similar effects for 23 
azithromycin and amoxicillin upon S. pneumoniae nasal carriage, while azithromycin has 24 
also been reported to have a modest suppressive effect upon NTHi colonisation in this patient 25 
 11 
population [14].  Only lower airway infection with M. catarrhalis appeared to be reduced in 1 
children who received macrolides, but this was not statistically significant. In contrast, beta-2 
lactam antibiotics had little impact on decreasing lower airway infection. 3 
 4 
 4.1 Impact of antibiotics upon resistance 5 
Although children who received macrolides were less likely to carry S. pneumoniae, they 6 
were more likely to be colonised by azithromycin-resistant S. pneumoniae or to have lower 7 
airway infection with azithromycin-resistant strains. This suggests that macrolide use 8 
eliminated mainly susceptible strains, consistent with reports of increased carriage of 9 
azithromycin-resistant S. pneumoniae strains in Indigenous Australian children following 10 
azithromycin treatment for acute otitis media [14] and trachoma [15].  11 
 12 
Levels of S. pneumoniae azithromycin resistance in this study were higher than those found 13 
in Indigenous children of a similar age in cross-sectional surveys in remote NT communities 14 
in 2003 and 2005 and in both instances involved a diverse range of non-vaccine 15 
pneumococcal serotypes [16]. As a proportion of S. pneumoniae carriage-positive children, 16 
azithromycin resistance was 6% in the community surveys compared with 34% (Table 4, 17 
13/38) in the present study.  While higher azithromycin resistance in our study was associated 18 
with recent macrolide use, it was also higher than reported previously in children who had not 19 
recently received macrolides (Table 4, 4/27 or 15% of carriage-positive children). This may 20 
be due to previous azithromycin exposure in these children or to increased azithromycin use 21 
in the general NT population, where it is used for treating trachoma and for some respiratory 22 
and sexually transmitted infections.    23 
 24 
 12 
Azithromycin resistance in NTHi has not previously been reported in this population. Most 1 
H. influenzae strains have an intrinsic macrolide-efflux mechanism and azithromycin MICs 2 
of 0.25-4 mg/L [17].  These strains are now defined in the latest EUCAST guidelines as 3 
intermediate-resistant [13]. In a study of over 6000 isolates, only 1.3% had high-level 4 
macrolide resistance (MIC >4 mg/L) due to ribosomal alterations, while 1.8% were defined 5 
as hypersusceptible (MIC <0.25 mg/L) [17].  In our study, high-level azithromycin resistance 6 
was detected in 13% of children with NTHi lower airway infection. It seems likely that, as 7 
with S. pneumoniae, azithromycin-resistant NTHi strains have been selected at the individual 8 
or population level by macrolide use.  9 
 10 
Children who received beta-lactam antibiotics were also significantly more likely to have 11 
lower airway infections with ampicillin-resistant NTHi. Overall, 10% of children in this study 12 
carried BL-positive NTHi. While this is lower than reported elsewhere (e.g. 26% in North 13 
America [18]), it is higher than the 5% previously reported in this population [14]. As 14 
expected, most M. catarrhalis isolates in our study were BL-positive. We did not test for 15 
azithromycin susceptibility as M. catarrhalis is regarded as being almost universally 16 
susceptible to azithromycin. A recent study in Western Australia, which included Indigenous 17 
children, reported that all 261 M. catarrhalis strains tested were susceptible to azithromycin 18 
[19]. In our study, azithromycin susceptibility is the most likely explanation for M. 19 
catarrhalis lower airway infections being less prevalent in children who had received 20 
macrolides. 21 
 22 
4.2 Clinical relevance of azithromycin resistance 23 
The level of azithromycin resistance observed in our study is concerning. While azithromycin 24 
is reported to be effective against susceptible strains of S. pneumoniae, the relevant MIC 25 
 13 
breakpoint is controversial and depends upon the site of infection.  Most treatment failures 1 
have been reported for community-acquired pneumonia (CAP) [20] and generally with 2 
azithromycin MIC ≥8 mg/L [10].  Treatment failure has also been reported for S. pneumoniae 3 
lower airway infections with MIC ≥4 mg/L [21] and for otitis media with MIC >1 mg/L [22].   4 
Although guidelines suggest a 25% rate of high-level S. pneumoniae resistance (MIC ≥16 5 
mg/L) as a threshold at which macrolides should no longer be used for CAP, some authors 6 
believe failure to consider low-level resistance will result in higher rates of morbidity and 7 
mortality because of discordant therapy [23].  In our study we found azithromycin-resistant 8 
(MIC >4 mg/L) S. pneumoniae in 59% of specimens from children with S. pneumoniae lower 9 
airway infection, and all but one tested isolate had MIC ≥16 mg/L. As a result, treating 10 
clinicians may be faced with treatment failure in this setting.  11 
 12 
Much less is known about macrolide resistance and its clinical significance in H. influenzae 13 
infection. An approach utilising pharmacokinetic and pharmacodynamic (PK/PD) modelling 14 
reported that none of 148 respiratory NTHi isolates from children attending two United States 15 
paediatric hospitals between 2005 and 2007 were susceptible with PK/PD breakpoints 16 
compared to 87% using Clinical and Laboratory Standards Institute breakpoints [24].  The 17 
EUCAST guidelines have taken into account the intrinsic macrolide efflux mechanism 18 
possessed by most NTHi strains and have lowered their clinical breakpoints to include these 19 
isolates [13]. Nevertheless, while some experts claim that azithromycin has no clinically 20 
useful activity against H. influenzae [25], others report that azithromycin is effective for 21 
treating chronic lower airway infections, including those caused by H. influenzae [5,6,26].  22 
Unfortunately, correlation between macrolide MICs and clinical outcome is weak for H. 23 
influenzae [13]. As with S. pneumoniae, different MIC breakpoints may be needed according 24 
 14 
to the site of infection. When assessing the clinical responses to azithromycin it is also 1 
important to consider the immunomodulatory properties of this agent [27].   2 
 3 
4.3 Limitations 4 
Our study has important limitations. As an observational, point-prevalence study, the impact 5 
of previous exposure to macrolide (or other) antibiotics upon respiratory bacterial pathogens 6 
could not be analysed. A randomised, placebo-controlled trial of long-term azithromycin in 7 
Indigenous children with bronchiectasis (ACTRN1261000038 3066) is currently underway 8 
and should help to further address the effects of azithromycin upon respiratory flora.  9 
 10 
In addition, BAL fluid cultures may have under-diagnosed lower airway infections in patients 11 
with multi-lobar disease through sampling only from a single lobe [28]. Similarly, the 12 
proportions of antibiotic-resistant strains identified are likely to have been underestimated by 13 
only performing antibiotic susceptibility testing on a limited number of colonies from each 14 
culture plate.  Small subject numbers may have led to type II errors in some sub-analyses, 15 
most notably for M. catarrhalis.  In this regard the numbers of study participants harbouring 16 
Staphylococcus aureus in their nasopharynx (n=15) or associated with lower airway infection 17 
(n=3) were too small to analyse. Worryingly, macrolide-resistant S. aureus isolates were 18 
detected in nasopharyngeal and BAL-fluid cultures from 12 (80%) and 2 (67%) children 19 
carrying S. aureus respectively (data not shown). As azithromycin is associated with rapid 20 
emergence of macrolide-resistant strains of S. aureus in patients with CF [29], a larger study 21 
is being undertaken.  Finally, this is a high risk group, and these findings may not be 22 
generalisable to other settings.  23 
 24 
4.4 Conclusions 25 
 15 
Our data show an association between reduced nasopharyngeal carriage of respiratory 1 
bacterial pathogens in children who had received macrolide or beta-lactam antibiotics 2 
recently, but no such association was observed for lower airway infection. Only infection 3 
with M. catarrhalis was reduced in children who had received macrolides, suggesting that 4 
azithromycin may be effective in clearing M. catarrhalis from the lungs of Indigenous 5 
children with bronchiectasis, or perhaps in preventing lower airway colonisation. Macrolide 6 
use was however associated with increased levels of carriage and infection with 7 
azithromycin-resistant S. pneumoniae, while the persistence of NTHi infection in the lungs of 8 
children receiving azithromycin suggests that azithromycin is ineffective against most NTHi. 9 
These findings are consistent with recent reports, including in vitro studies, which found that 10 
azithromycin was highly effective against M. catarrhalis and susceptible S. pneumoniae, 11 
while its effect upon H. influenzae was limited [30]. A randomised, placebo-controlled trial 12 
of long-term azithromycin therapy in our population of Indigenous children with non-CF 13 
bronchiectasis will help to determine whether increased levels of resistance in S. pneumoniae 14 
and NTHi will negate any of the clinical benefits.  15 
 16 
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 Table 1: Nasopharyngeal carriage by antibiotic use 1 
Antibiotics  None 
N  
(%) 
Any 
N  
(%) 
Macrolide 
N  
(%) 
Beta-lactam 
N  
(%) 
Both 
N  
(%) 
Other 
N  
(%) 
Total 
N  
(%) 
Children 39 65 35 22 4 4 104 
 
S. pneumoniae 25  
(64) 
13  
(20) 
10  
(29) 
2  
(9) 
1  
(25) 
0  
(0) 
38  
(37) 
 
H. influenzae 23  
(59) 
29  
(45) 
15  
(43) 
11  
(50) 
1  
(25) 
2  
(50) 
52
1
 
(50) 
 
M. catarrhalis 17  
(44) 
16  
(25) 
8  
(23) 
6  
(27) 
0  
(0) 
2  
(50) 
33  
(32) 
 
Any  pathogen 
(of the 3) 
32  
(82) 
37  
(57) 
20  
(57) 
12  
(55) 
2  
(50) 
3  
(75) 
69  
(66) 
 
All three  
pathogens 
11  
(28) 
5  
(8) 
4  
(11) 
1  
(5) 
0  
(0) 
0  
(0) 
16  
(15) 
 
2 
1
 Two children carried typeable (non-Hib) strains only. 3 
4 
 23 
Table 2: Lower airway infection (>10
4
 colony-forming units/mL of bronchoalveolar 1 
               lavage fluid) by antibiotic use 2 
Antibiotics  None 
N  
(%) 
Any 
N  
(%) 
Macrolide 
N  
(%) 
Beta-lactam 
N  
(%) 
Both 
N  
(%) 
Other 
N  
(%) 
Total 
N  
(%) 
Children 39 65 35 22 4 4 104 
 
S. pneumoniae 6  
(15) 
11  
(17) 
8  
(23) 
2  
(9) 
1  
(25) 
0  
(0) 
17  
(16) 
 
H. influenzae 13  
(33) 
19  
(29) 
9  
(26) 
7  
(32) 
1  
(25) 
2  
(50) 
32
1
 
(31) 
 
M. catarrhalis 5  
(13) 
7  
(11) 
1  
(3) 
4  
(18) 
0  
(0) 
2  
(50) 
12  
(12) 
 
Any pathogen 
(of the 3) 
15  
(38) 
27  
(42) 
16  
(46) 
8  
(36) 
1  
(25) 
2  
(50) 
42  
(40) 
 
All three 
pathogens 
3  
(8) 
1  
(2) 
0  
(0) 
1  
(5) 
0  
(0) 
0  
(0) 
4  
(4) 
 
3 
1
 All 32 children had nontypeable Haemophilus influenzae isolated from their lower airways. 4 
5 
 24 
Table 3:   Odds Ratio (OR) of antibiotic use for nasopharyngeal carriage and lower 1 
                 airway infection (>10
4
 colony-forming units/mL of bronchoalveolar lavage 2 
                 fluid) 3 
 
Pathogen 
Nasopharyngeal carriage Lower airway infection 
Macrolides
1
 
OR (95% CI) 
Beta-lactams
2
 
OR (95% CI) 
Macrolides
1
 
OR (95% CI) 
Beta-lactams
2
 
OR (95% CI) 
S. pneumoniae 0.22 
(0.08, 0.63) 
P<0.01 
0.07 
(0.01, 0.32) 
P<0.01 
1.65 
(0.46, 6.31) 
P=0.57 
0.72 
(0.11, 3.80) 
P=0.73 
 
H. influenzae 0.48 
(0.18, 1.31) 
P=0.17 
0.60 
(0.19, 1.82) 
P=0.32 
0.69 
(0.23, 2.05) 
P=0.62 
0.89 
(0.26, 2.90) 
P=1.00 
 
M. catarrhalis 0.33 
(0.11, 1.01) 
P=0.05 
0.39 
(0.11, 1.31) 
P=0.12 
0.18 
(0.00, 1.75) 
P=0.20 
1.24 
(0.22, 6.44) 
P=1.00 
 
Any pathogen 
(of the 3) 
0.28 
(0.09, 0.88) 
P<0.05 
0.26 
(0.07, 0.90) 
P<0.05 
1.24 
(0.46, 3.37) 
P=0.82 
0.85 
(0.26, 2.67) 
P=0.80 
1
 39 children who received macrolides versus 39 who received no antibiotics (N=78). 4 
2
 26 children who received beta-lactams versus 39 who received no antibiotics (N=65). 5 
 6 
7 
 25 
Table 4: Resistance in nasopharyngeal carriage by antibiotic use 1 
Antibiotics  None 
N  
Any 
N  
Macrolide 
N  
Beta-lactam 
N  
Both 
N  
Other 
N  
Total 
N  
Children 39 65 35 22 4 4 104 
S. pneumoniae  
Susceptible 14 2 2 0 0 0 16 
PenNS  
or AziR 
11 11 8 2 1 0 22 
PenNS only 8 1 0 1 0 0 9 
AziR only 3 8 6 1 1 0 11 
PenNS+AziR 0 2 2 0 0 0 2 
 
Nontypeable H. influenzae  
AziIR only 19 18 9 8 0 1 37
1
 
BLpos  
or AziR 
2 9 5 3 0 1 11 
BLpos only 1 7 3 3 0 1 8 
AmpR  2 5 2 2 0 1 7 
AziR only 0 2 2 0 0 0 2 
BLpos+AziR 1 0 0 0 0 0 1 
 
M. catarrhalis  
BLneg 2 1 1 0 0 0 3 
BLpos 15 15 7 6 0 2 30 
1
 None susceptible by European Committee on Antimicrobial Susceptibility Testing 2 
(EUCAST) criteria; MIC results not obtained for two nasopharyngeal swabs.  3 
 26 
Abbreviations: PenNS, oral penicillin non-susceptible (MIC > 0.12 mg/L); AziR, 1 
azithromycin resistant (MIC >4 mg/L); AziIR, azithromycin intermediate resistant (MIC 2 
>0.125 and ≤4 mg/L); AmpR, ampicillin-resistant (MIC ≥ 4 mg/L); BLneg, beta-lactamase 3 
negative; BLpos, beta-lactamase positive; MIC, minimum inhibitory concentration.  4 
  5 
 6 
7 
 27 
Table 5:    Resistance in lower airway infection (>10
4
 colony-forming units/mL of 1 
                  bronchoalveolar lavage fluid) by antibiotic use 2 
Antibiotics   None 
N  
Any 
N  
Macrolide 
N  
Beta-lactam 
N  
Both 
N  
Other 
N  
Total 
N  
Children 39 65 35 22 4 4 104 
S. pneumoniae   
Susceptible 2 1 1 0 0 0 3 
PenNS  
or AziR 
4 10 7 2 1 0 14 
PenNS only 3 1 0 1 0 0 4 
AziR only 0 8 6 1 1 0 8 
PenNS+AziR 1 1 1 0 0 0 2 
 
Nontypeable H. influenzae   
AziIR only 8 8 5 3 0 0 16
1
 
BLpos 
or AziR 
5 9 3 4 1 1 14 
BLpos only 3 7 1 4 1 1 10 
AmpR  3 6 0 4 1 1 9 
AziR only 2 2 2 0 0 0 4 
BLpos+AziR 0 0 0 0 0 0 0 
 
M. catarrhalis   
BLneg 0 0 0 0 0 0 0 
BLpos 5 7 1 4 0 2 12 
 28 
1
 None susceptible by EUCAST criteria; MIC results not obtained for two BAL specimens. 1 
Abbreviations: see Table 4.  2 
3 
 29 
Table 6: Serotypes isolated from 17 paired nasopharyngeal swab and bronchoalveolar 1 
lavage fluid cultures associated with Streptococcus pneumoniae lower airway infection 2 
in Indigenous Australian children with bronchiectasis 3 
Pair 
# 
Antibiotics received in 2 
weeks prior to bronchoscopy 
Serotypes in NP 
swab 
Serotypes in BAL fluid 
(>10
4
 CFU/mL) 
1 Azithromycin 21 (sens) 21 (sens), 10A (sens) 
2 Azithromycin  31 (AziR) 
5 Azithromycin  7F (AziR) 
9 Azithromycin  9N (AziR)  
10 Azithromycin 22F (AziR)  22F (AziR) 
14 Azithromycin 11A (AziR+PenNS) 11A (AziR+PenNS) 
15 Azithromycin  22F (AziR) 
16 Azithromycin 17F (AziR) 17F (AziR) 
4 Azithromycin, amoxicillin 6A (AziR) 6A (AziR) 
11 Amoxicillin 23F (AziR) 23F (AziR) 
13 Cefotaxime, benzylpenicillin  6C (PenNS), 19F (PenNS) 
3 None 6C (AziR) 6C (AziR), 19F (PenNS) 
6 None 16F (PenNS) 16F (PenNS) 
7 None 16F (PenNS) 16F (PenNS) 
8 None 9N (sens) 9N (sens) 
12 None 19A (PenNS) 19A (PenNS) 
17 None 15A (sens) 15A (sens) 
Abbreviations: BAL, bronchoalveolar lavage fluid; CFU, colony forming units; NP, 4 
nasopharyngeal; AziR, azithromycin resistant (MIC >4 mg/L); PenNS, oral penicillin non-5 
susceptible (MIC >0.12 mg/L); sens, susceptible to penicillin and azithromycin. 6 
7 
 30 
Table 7: Odds Ratio (OR) of antibiotic use for antimicrobial resistance  1 
 
Pathogen 
Nasopharyngeal carriage Lower airway infection 
Macrolides
1
 
OR (95% CI) 
Beta-lactams
2
 
OR (95% CI) 
Macrolides
1
 
OR (95% CI) 
Beta-lactams
2
 
OR (95% CI) 
Spn AziR 4.58 
(1.14, 21.7) 
P<0.05 
0.51 
(0.05, 2.60) 
P=0.51 
8.13 
(1.47, 81.3) 
P<0.01 
0.73 
(0.07, 4.03) 
P=1.00 
Spn PenNS 0.34 
(0.03, 1.77) 
P=0.20 
0.27 
(0.01, 2.11) 
P=0.28 
0.32 
(0.01, 3.01) 
P=0.41 
0.58 
(0.01, 5.62) 
P=1.00 
NTHi AmpR
3
 0.65 
(0.06, 4.23) 
P=0.71 
1.22 
(0.11, 8.03) 
P=1.00 
0.19 
(0.00, 1.51) 
P=0.15 
4.40 
(0.85, 23.9) 
P<0.05 
NTHi AziR 3.66 
(0.18, 219) 
P=0.30 
0.00 
(0.00, 3.98) 
P=1.00 
1.72 
(0.12, 24.6) 
P=0.63 
0.00 
(0.00, 2.79) 
P=0.57 
NTHi AziIR 0.47 
(0.18, 1.16) 
P=0.10 
0.99 
(0.36, 2.70) 
P=1.00 
0.53 
(0.17, 1.54) 
P=0.25 
1.43 
(0.48, 4.20) 
P=0.60 
Mc BLpos 0.40 
(0.13, 1.12) 
P=0.07 
0.68 
(0.20, 2.04) 
P=0.62 
0.13 
(0.00, 0.97) 
P<0.05 
1.59 
(0.32, 6.64) 
P=0.49 
1
 39 children who received macrolides versus 65 who received no macrolides (N=104) 2 
2
 26 children who received beta-lactams versus 78 who received no beta-lactams (N=104)  3 
3
 Similar results were obtained for BLpos NTHi (not shown). 4 
5 
 31 
Abbreviations: Spn, Streptococcus pneumoniae; AziR, azithromycin resistant (MIC >4 1 
mg/L); PenNS, oral penicillin non-susceptible (MIC >0.12 mg/L); NTHi, nontypeable 2 
Haemophilus influenzae; AziIR, azithromycin intermediate resistant (MIC >0.125 and ≤4 3 
mg/L); AmpR, ampicillin-resistant (MIC ≥4 mg/L); Mc, Moraxella catarrhalis; BLneg, beta-4 
lactamase negative; BLpos, beta-lactamase positive; MIC, minimum inhibitory concentration. 5 
 6 
